Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine
Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine
复制标题
DOI：
10.1006/biol.1999.0238
复制
发表时间：
2000-03-01
期刊：
影响因子：
1.7
通讯作者：
Jones, C
中科院分区：
文献类型：
--
作者：
Lemercinier, X;Martinez-Cabrera, I;Jones, C
Typhoid fever remains a major killer, causing approximately 600 000 deaths per year and many millions more people will su# er a non-fatal infection. 1 Multi-drug resistance is an increasingly common problem with Salmonella typhi, and e# ective treatment requires access to expensive third generation cephalosporin and fluoroquinoline antibiotics, purchase of which imposes a huge strain on Third World health budgets. 2 The purified Vi capsular polysaccharide (CPS) 3 from S. typhi is currently used as a vaccine and has an e# icacy of about 70%. 4–6 Each dose of the vaccine containing 25 μg of CPS. 7 Two key tests in the control of the bulk polysaccharide are an immunological identity test and an estimation of the degree of O-acetylation. The O-acetyl group has been shown to be a dominant epitope on the polysaccharide8 and to be immunodominant. 9 Early attempts to produce an e# ective Vi vaccine failed due to de-O-acetylation of the CPS. 10 Current WHO guidelines and the EP monograph for the vaccine bulk prescribe ‘‘a suitable immunochemical method’’to identify the CPS and the Hestrin colorimetric test to assess the degree of O-acetylation. 11, 12
